A new clinical study from the US shows a reduction in contamination risk of 97% when using a closed system transfer device (CSTD) to administer hazardous drugs.
The US study* involved 13 cancer centres across the United States and the findings demonstrated that the CSTD reduced surface contamination by cyclophosphamide and fluorouracil during compounding and simulated administration.
When the hospitals did not use a CSTD, the level of antimitotic contamination during administration was 78%. This rate decreases to 2.6% when using a CSTD, which represents a reduction of nearly 97% in contamination rate. Furthermore, participants reported that the CSTD was easy to use.
- Bartel, S et al Multicenter evaluation of a new closed system drug-transfer device in reducing surface contamination by antineoplastic hazardous drugs American Journal of Health-System Pharmacy 2018 Volume 75
Download the paper in full from http://www.qimono.co.uk/papers-supporting-cstd/